FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Zaks Tal Zvi
2. Issuer Name and Ticker or Trading Symbol

Moderna, Inc. [ MRNA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O MODERNA, INC., 200 TECHNOLOGY SQUARE
3. Date of Earliest Transaction (MM/DD/YYYY)

11/23/2020
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/23/2020  M(1)  5000 A$12.21 5000 D  
Common Stock 11/23/2020  M(1)  10000 A$19.15 15000 D  
Common Stock 11/23/2020  S(1)  1440 D$99.31 (2)13560 D  
Common Stock 11/23/2020  S(1)  6836 D$100.12 (3)6724 D  
Common Stock 11/23/2020  S(1)  6724 D$101.21 (4)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $12.21 11/23/2020  M (1)    5000   (5)2/23/2027 Common Stock 5000 $0 17945 D  
Stock Option (Right to Buy) $19.15 11/23/2020  M (1)    10000   (6)8/10/2026 Common Stock 10000 $0 34790 D  

Explanation of Responses:
(1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
(2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.70 to $99.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.72 to $100.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(5) 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
(6) This option is fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139


Chief Medical Officer

Signatures
/s/ Lori Henderson, as Attorney-in-Fact11/24/2020
**Signature of Reporting PersonDate

Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Moderna Charts.